Previous 10 | Next 10 |
Harrow Health, Inc. (HROW) Q3 2021 Earnings Conference Call November 9, 2021 4:45 PM ET Company Participants Jamie Webb – Director of Communications and Investor Relations Mark L. Baum – Chief Executive Officer Andrew Boll – Chief Financial Officer Conference Call Partici...
Harrow Health (NASDAQ:HROW): Q3 GAAP EPS of -$0.31 misses by $0.28. Revenue of $18.7M (+29.9% Y/Y) beats by $1.25M. Press Release For further details see: Harrow Health EPS misses by $0.28, beats on revenue
Revenues Reach Record Levels for Fifth Consecutive Quarter Highlights for Third Quarter 2021: Record revenues of $18.7 million, a 30% increase compared with $14.4 million for the prior-year period; Gross margin of 74% consistent with prior-year period; Acquired...
Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic‑focused healthcare company, today announced that it will release its financial results for the third quarter and nine months ended September 30, 2021, on Tuesday, November 9, 2021, after the market close. The Company will also pos...
Melt Expects to Dose First Patient in MELT-300 Phase 2 Study During September 2021 Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic-focused healthcare company, and Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing first-in-class medicines for se...
The company can grow efficiently; as revenue grows, the Cost of Revenue and SG&A expenses as a % of revenue decrease. Management expects this trend to continue. According to The National Eye Institute, over 24 million Americans are affected by cataracts. The market potential allow...
Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic‑focused healthcare company, today announced that it has entered into an agreement with Wakamoto Pharmaceutical Co., Ltd. to acquire the U.S. and Canadian commercial rights for drug candidate MAQ-100, a preservative-free triamcinol...
SRK Capital, LLC provides investment management services to an investment partnership, SRK Fund I, LP. SRK Fund I, LP appreciated +59.17% during the first half of 2021. In contrast, the S&P 500 and the Russell 2000 gained +15.25% and 17.53%, respectively. Over the next year I ...
The following slide deck was published by Harrow Health, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Harrow Health, Inc. 2021 Q2 - Results - Earnings Call Presentation
Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that Mark L. Baum, Chief Executive Officer, and Andrew Boll, Chief Financial Officer, will participate in two upcoming virtual investor conferences. Harrow Health will participate in the ...
News, Short Squeeze, Breakout and More Instantly...
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on August 8, 2024 Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will report its financial results for the second quarter ended June 30, 2024, on Wednesday, August...
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that its management team would attend the 2024 American Society of Retina Specialists (ASRS) Annual Meeting, taking place in Stockholm, Sweden, from July 17-20, 2024. The ASRS Annual Meeting brings tog...
Contract Enhances Purchasing Power for 340B Prime Vendor Program (PVP) Participants; Aligns with Harrow’s Mission to Make Its Products Accessible and Affordable Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that as of July 1, 2024, ...